Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, tasimelteon (Hetlioz®) cannot be endorsed for use within NHS Wales for the treatment of non-24-hour sleep-wake disorder (non-24) in totally blind adults. |
||
|
||
Medicine details |
||
| Medicine name | tasimelteon (Hetlioz®) | |
| Formulation | 20 mg hard capsules | |
| Reference number | 1077 | |
| Indication | For the treatment of non-24-hour sleep-wake disorder (non-24) in totally blind adults. |
|
| Company | Vanda Pharmaceuticals Inc | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/12/2015 | |
| Date of issue | 10/12/2015 | |